RAD301

DEVELOPMENT STEP phase-1
SPONSOR MATRIX Radiopharm Theranostics [RADX]
MECHANISM TARGET // UNMAPPED_TARGET

[THERAPEUTIC_PROFILE]

Target Indications

Integrin αvβ6 Positive Tumors, Pancreatic cancer/ NSCLC

Mechanism Abstract

A peptide bearing Ga68 isotope

[CLINICAL_TRIALS_REGISTRY]

TOTAL EXTRACTED1
RECRUITING STATUS1
COMPLETED RUNS0
REGISTRY & PHASE
TESTED CONDITION
STUDY TITLE & LIFECYCLE TIMELINES
STATUS
➔
P-1NCT05799274
Healthy VolunteersPancreatic Ductal Adenocarcinoma+5 more
N=9Est. Finish: 2026-05
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
recruiting